Comparative efficacy of oral Ketamine vs. Electroconvulsive therapy in moderate to severe depression: A randomized controlled trial.
试验速览
- 阶段
- Phase 3 4
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- change in MADRS score
研究概览
简要总结
The proposed study aims to conduct a randomized, controlled, parallel-group clinical trial at the Department of Psychiatry, AIIMS, Bhubaneswar. The study will include patients diagnosed with Moderate and Severe Depressive episodes based on ICD 10 (DCR) and DSM 5 criteria, who meet all the specified inclusion and exclusion criteria.Randomization will be performed using computer-generated random numbers, with an allocation ratio of 1:1, to assign the patients into two treatment groups. Sociodemographic and clinical data of the patients will be collected using predetermined forms. Baseline assessments of the patients’ MADRS (Montgomery-Åsberg Depression Rating Scale) scores will be conducted, and the study will be blinded to the assessors. The experimental group will receive oral ketamine as the treatment, starting with a dosage of 150mg in the first session, followed by 150-175mg three times a week for a duration of 2 weeks. (22) (16)and the control group would receive bitemporal Electroconvulsive Therapy up to 3 times a week for 2 weeks. ECT is to be administered at the lowest dose that elicits a generalized seizure. Both groups treated with a fixed course of alternate day sessions thrice a week for 2 weeks (total 6 sessions). All outcome measures with assessed at baseline and at 1 week, 2 weeks, 3 weeks, and 6 weeks.
The two groups would be followed for 6 weeks, at the completion of which all the patients would be reassessed. The follow-up assessment would involve a re-evaluation of the MADRS and other assessments to see for any change. The data thus collected would be analysed, and compared within and in between the study groups and statistical tests would be applied for drawing conclusions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Outcome Assessor Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)(—)
- 性别
- All
入选标准
- •All patients coming for treatment at the OPD and IPD of the Department of Psychiatry fulfilling the following are included: a) People with Moderate to Severe Depressive episode according to criteria in DSM 5 and ICD 10 RCD.
- •b) Aged between 18 to 65 years c) American Society of Anaesthesiologists (ASA) score of 1, 2 or stable 3 d) With Informed consent from the Legally Authorised Relative.
排除标准
- •Severe hepatic or renal impairment b.
- •Uncontrolled hypertension, history of significant cardiac arrhythmias, history of substance dependence, history of seizure disorder or organic brain disorder, pregnancy or breastfeeding c.
- •Concomitant psychotic disorder.
- •Non-Consenting e.
- •History of ketamine allergy f.
- •Receipt of ECT or ketamine in the past 6 months.
结局指标
主要结局
change in MADRS score
时间窗: baseline and one week after completion of final intervention (Week 3)
次要结局
- To compare MADRS scores between ECT and ketamine groups(Base line 1 and 2 weeks)
- compare MADRS response and remission rates(Base line 1 and 2 weeks)
研究者
Susanta Kumar Padhy
AIIMS Bhubaneswar
